Hostname: page-component-848d4c4894-r5zm4 Total loading time: 0 Render date: 2024-07-02T05:46:22.919Z Has data issue: false hasContentIssue false
  • English
  • Français

Do fluoroquinolones commonly cause arthropathy in children?

Published online by Cambridge University Press:  21 May 2015

Clinton T. Forsythe  and
Michael E. Ernst
Clinton T. Forsythe
Affiliation:
University of Minnesota Medical Centre, Fairview, Minn.
Michael E. Ernst*
Affiliation:
Division of Clinical and Administrative Pharmacy, College of Pharmacy and the Department of Family Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa
*
Department of Family Medicine/01291-A PFP, University of Iowa, 200 Hawkins Drive, Iowa City IA 52242; michael-ernst@uiowa.edu

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

The objective of this paper was to review the relation between fluoroquinolone (FQ) use and arthropathy in children.

Methods:

The biomedical literature from January 1980 to February 2007 was searched using PubMed. Key search terms included fluoroquinolones, arthropathy, tendinopathy and children. Literature was included if it was a clinical trial or meta-analysis examining the use of 1 or more FQs in a pediatric human population and if it had a primary outcome measure of reported incidence of arthropathy or tendinopathy. Articles were excluded if the primary outcome measure was efficacy of an FQ in a particular pediatric disease state, and evaluated safety was a secondary end point.

Results:

Data was reviewed from 4 large retrospective studies. Three of the 4 studies failed to find a significant link between musculoskeletal injury and FQ treatment. One study reported a correlation between use of pefloxacin and arthropathy, but the authors' conclusions supported the use of FQs in select pediatric cases.

Conclusion:

Arthropathy that occurs as a result of FQ use in children has not been adequately supported by published data from safety trials in human children. Concerns about arthropathy with FQs should not preclude their use by emergency physicians when appropriate and necessary in pediatric patients.

Keywords

fluoroquinolonestendinopathyadverse effectspediatrics
Type
Original Research • Recherche originale
Information
Canadian Journal of Emergency Medicine , Volume 9 , Issue 6 , November 2007 , pp. 459 - 462
Copyright
Copyright © Canadian Association of Emergency Physicians 2007

References

1.McDonald, DF, Short, HB. Usefulness of nalidixic acid in treatment of urinary tract infections. Antimicrobial Agents Chemother (Bethesda) 1964;64:628–31.Google Scholar
2.Schaad, UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am 2005;19:617–28.Google Scholar
3.Burkhardt, JE, Walterspiel, JN, Schaad, UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997;25:1196–204.Google Scholar
4.Chalumeau, M, Tonnelier, S, D’Athis, P, et al. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics 2003;111:e714–9.Google Scholar
5.Drossou-Agakidou, V, Roilides, E, Papakyriakidou-Koliouska, P, et al. Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year. Pediatr Infect Dis J 2004;23:346–9.CrossRefGoogle ScholarPubMed
6.Yee, CL, Duffy, C, Gerbino, PG, et al. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 2002;21:525–9.Google Scholar
7.Sabharwal, V, Marchant, CD. Fluoroquinolone use in children. Pediatr Infect Dis J 2006;25:257–8.Google Scholar